At HyTest, scientific research is a cornerstone of our product development. An integral part of research is made up of the articles that are published in peer reviewed journals. This year, three different studies conducted by our R&D team have already been published– specifically, two research articles and one review.

1)    Review of BNP and NT-proBNP standardization – receive a free copy!

“Standardization of BNP and NT-proBNP immunoassays in light of the diverse and complex nature of circulating BNP-related peptides” has been published as a chapter in Advances In Clinical Chemistry.

Both BNP and NT-proBNP are established markers of heart failure that are used in clinical practice for several purposes: to identify or exclude heart failure, to assess the severity of the disease, for risk stratification, as well as to monitor the response to therapy. In order to measure BNP or NT-proBNP, there are several diagnostic assays available that are widely used in clinical practices. Unfortunately, the results of measurements that are obtained with different assays are not sufficiently comparable and this can easily cause problems in daily practice.

The aim of this review is to “summarize the available data on the complex nature of BNP-related peptides, specificity for existing BNP and NT-proBNP immunoassays and to discuss potential approaches for the standardization of BNP and NT-proBNP measurements.”

In order to receive a free copy of the review, please click on the link below. Please note that the link is valid up until May 31, 2018.  

Semenov, A. G. & Feygina, E. E. Standardization of BNP and NT-proBNP Immunoassays in Light of the Diverse and Complex Nature of Circulating BNP-Related Peptides. in Advances in Clinical Chemistry 85, 1–30 (Elsevier, 2018).

2)    Research article about glycosylated and non-glycosylated NT-IGFBP-4. Open access.

Along with novel data regarding the regulation of bioavailability of IGF hormone by IGFBP-4 glycosylation, this article describes HyTest’s prototype HRP-based immunoassay for NT-IGFBP-4. The assay is validated according to the requirements of clinical journals and it is utilized for NT-IGFBP-4 measurements in the samples from acute coronary syndrome patients.

Konev, A. A. et al. Glycosylated and non-glycosylated NT-IGFBP-4 in circulation of acute coronary syndrome patients. Clinical Biochemistry (2018). doi:10.1016/j.clinbiochem.2018.03.004

3)      Research article about cTnI and its proteolytic fragments in blood. Open Access Early Release.

Cardiac troponin I is a 209 amino acid long protein that is known to be present in the blood of acute myocardial infarction (AMI) patients as a pool of intact protein and its differently truncated forms. The truncation might influence a reliable detection of this marker in an immunoassay if the antibodies utilized in the assay were poorly chosen. The aim of this study was to investigate in more detail what the ratio of the different cTnI forms was at different time points following AMI, with the objective of determining the most stable parts of cTnI suitable for immunodetection.

Katrukha, I. A. et al. Full-Size Cardiac Troponin I and Its Proteolytic Fragments in Blood of Patients with Acute Myocardial Infarction: Antibody Selection for Assay Development. Clin. Chem. (2018). doi:10.1373/clinchem.2017.286211